Literature DB >> 25619682

Injection scheme for intravitreal bevacizumab therapy for macular oedema due to central retinal vein occlusion: results of a multicenter study.

Kai Januschowski1, Spyridon Dimopoulos1, Peter Szurman1,2, Nicolas Feltgen3, Bernhard Spitzer4, Amelie Pielen5, Matus Rehak6, Georg Spital7, Carsten H Meyer8, Gesine B Szurman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25619682     DOI： 10.1111/aos.12600

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN： 1755-375X            Impact factor:   3.761


× No keyword cloud information.
  4 in total

1.  Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion.

Authors:  Kai Januschowski; Nicolas Feltgen; Amelie Pielen; Bernhard Spitzer; Matus Rehak; Georg Spital; Spyridon Dimopoulos; Carsten H Meyer; Gesine B Szurman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-09-08       Impact factor: 3.117

2.  Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion.

Authors:  Gesine B Szurman; Carsten H Meyer; Nicolas Feltgen; Amelie Pielen; Bernhard Spitzer; Matus Rehak; Georg Spital; Spyridon Dimopoulos; Peter Szurman; Kai Januschowski
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-02-21       Impact factor: 3.117

3.  Hydrofluoric Acid and Other Impurities in Toxic Perfluorooctane Batches.

Authors:  Dirk-Henning Menz; Nicolas Feltgen; Thorsten Lechner; Helge Menz; Bernd-Kristof Müller; Joachim Dresp; Hans Hoerauf
Journal:  Transl Vis Sci Technol       Date:  2019-05-29       Impact factor: 3.283

4.  Individualized treat-and-extend regime for optimization of real-world vision outcome and improved patients' persistence.

Authors:  Ingo Volkmann; Katharina Knoll; Mareile Wiezorrek; Oliver Greb; Carsten Framme
Journal:  BMC Ophthalmol       Date:  2020-03-30       Impact factor: 2.209
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.